Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium

Author's Avatar
Feb 16, 2019
Article's Main Image

-- Clinical study explored Calithera’s lead compound in combination with cabozantinib in patients with advanced renal cell carcinoma -